TUMOR TARGETING. Drug-loaded nanoparticles can be used to target selective cancer cells resulting in the localization of the therapeutic action, which is expected to prevent the typical side-effects usually encountered with conventional chemotherapeutics. We are developing colloidal and biomimetic nanoparticles that are intended to improve the targeting efficiency and bioavailability of drugs.

 

 

 

INFLAMMATORY DISEASES. Bioengineered nanoparticles can be developed to localize, monitor and quantify the early stages of inflammatory bowel diseases (IBDs), particularly Crohn disease and ulcerative colitis inflammatory diseases, and to treat aggressive inflammatory disorders including IBDs, rheumatoid arthritis, transplant rejection, edema, sepsis, and other inflammatory conditions.

 

 

ANTIVIRAL THERAPEUTICS. Nanotechnology has potential in HIV treatment by two approaches: 1)improving the pharmacokinetic properties of antiretroviral drugs, and 2) assisting drugs to cross the biological barriers (e.g., the blood brain barrier) to target the virus reservoirs.

 

ALTERNATIVE ADMINISTRATION ROUTES TO THE INTRAVENOUS ONE. Nanotechnology has potential in HIV treatment by two approaches: 1)improving the pharmacokinetic properties of antiretroviral drugs, and 2) assisting drugs to cross the biological barriers (e.g., the blood brain barrier) to target the virus reservoirs.

 

DIAGNOSIS AND THERAPIES WITH NANOPARTICLES (THERANOSTICS)